156 related articles for article (PubMed ID: 31086807)
1. Different MRI patterns in MS worsening after stopping fingolimod.
Lapucci C; Baroncini D; Cellerino M; Boffa G; Callegari I; Pardini M; Novi G; Sormani MP; Mancardi GL; Ghezzi A; Zaffaroni M; Uccelli A; Inglese M; Roccatagliata L
Neurol Neuroimmunol Neuroinflamm; 2019 Jul; 6(4):e566. PubMed ID: 31086807
[TBL] [Abstract][Full Text] [Related]
2. q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
Tanikawa M; Nakahara J; Hata J; Suzuki S; Fujiyoshi K; Fujiwara H; Momoshima S; Jinzaki M; Nakamura M; Okano H; Takahashi S; Suzuki N
J Neurol Sci; 2017 Feb; 373():352-357. PubMed ID: 28088313
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up.
Hersh CM; Love TE; Cohn S; Hara-Cleaver C; Bermel RA; Fox RJ; Cohen JA; Ontaneda D
Mult Scler Relat Disord; 2016 Nov; 10():44-52. PubMed ID: 27919497
[TBL] [Abstract][Full Text] [Related]
5. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
[TBL] [Abstract][Full Text] [Related]
6. Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study.
Maunula A; Atula S; Laakso SM; Tienari PJ
Mult Scler Relat Disord; 2024 Jan; 81():105134. PubMed ID: 37980790
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
[TBL] [Abstract][Full Text] [Related]
8. Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases.
Sánchez P; Meca-Lallana V; Vivancos J
Mult Scler Relat Disord; 2018 Oct; 25():95-98. PubMed ID: 30056362
[TBL] [Abstract][Full Text] [Related]
9. Tumefactive demyelinating lesions: A comprehensive review.
Algahtani H; Shirah B; Alassiri A
Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
[TBL] [Abstract][Full Text] [Related]
10. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
[TBL] [Abstract][Full Text] [Related]
11. No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Kolodny S; Silva D; Medin J; Weinstock-Guttman B;
Curr Med Res Opin; 2018 Aug; 34(8):1431-1440. PubMed ID: 29648900
[TBL] [Abstract][Full Text] [Related]
12. Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients.
Bianco A; Lucchini M; Totaro R; Fantozzi R; De Luca G; Di Lemme S; Presicce G; Evangelista L; Di Tommaso V; Pastorino R; De Fino C; De Arcangelis V; Centonze D; Mirabella M
Neurotherapeutics; 2021 Oct; 18(4):2598-2607. PubMed ID: 34494237
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis.
Oommen VV; Tauhid S; Healy BC; Chua AS; Malik MT; Diaz-Cruz C; Dupuy SL; Weiner HL; Chitnis T; Bakshi R
J Neuroimaging; 2016; 26(2):184-7. PubMed ID: 26445919
[TBL] [Abstract][Full Text] [Related]
15. Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R; Medin J; Khan N; Korn JR; Chitnis T; Naismith RT; Alvarez E; Dwyer MG; Bergsland N; Carl E; Silva D; Weinstock-Guttman B;
Mult Scler Relat Disord; 2019 Jan; 27():65-73. PubMed ID: 30342416
[TBL] [Abstract][Full Text] [Related]
16. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
[No Abstract] [Full Text] [Related]
17. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
[TBL] [Abstract][Full Text] [Related]
18. Severe Exacerbation of Multiple Sclerosis Following Withdrawal of Fingolimod.
Fragoso YD; Adoni T; Gomes S; Goncalves MVM; Parolin LF; Rosa G; Ruocco HH
Clin Drug Investig; 2019 Sep; 39(9):909-913. PubMed ID: 31152369
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of disease activity after fingolimod discontinuation in older patients previously stable on treatment.
Pantazou V; Pot C; Du Pasquier R; Le Goff G; Théaudin M
Mult Scler Relat Disord; 2021 Jun; 51():102918. PubMed ID: 33838521
[TBL] [Abstract][Full Text] [Related]
20. Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.
Williams MJ; Johnson K; Trenz HM; Korrer S; Halpern R; Park Y; Herrera V
Curr Med Res Opin; 2018 Jan; 34(1):107-115. PubMed ID: 28857632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
